MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'highlights'. Sat, 03 Sep 2011 02:30:02 +0100 http://www.medworm.com/index.php?rid=4934740&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F11%2F2011-asco-exelixis-reports-expanded-cabozantinib-xl184-phase-ii-data-for-advanced-ovarian-cancer-six-deaths-reported%2F Exelixis, Inc. reported expanded Phase 2 study data with respect to cabozantinib (XL184) use in advanced ovarian cancer patients at the recent 2011 American Society of Clinical Oncology Annual Meeting. The overall solid tumor Phase 2 safety and tolerability data reference six deaths, including two ovarian cancer patients. Exelixis, Inc. reported expanded Phase 2 study [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4934740 Sat, 11 Jun 2011 16:10:03 +0100 4934740 http://www.medworm.com/index.php?rid=4921689&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F09%2F2011-asco-additional-phase-iii-study-data-support-the-potential-role-of-avastin-in-newly-diagnosed-recurrent-ovarian-cancer%2F Positive results from two bevacizumab (Avastin®) phase III clinical studies were presented at the 2011 American Society of Clinical Oncology Annual Meeting on June 4. The data reported add to the growing body of evidence in support of bevacizumab use to treat recurrent and newly-diagnosed ovarian cancer. Positive results from two bevacizumab (Avastin®) phase III [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4921689 Thu, 09 Jun 2011 23:15:13 +0100 4921689 http://www.medworm.com/index.php?rid=4902643&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F05%2F2011-asco-ec145-demonstrates-85-percent-improvement-in-progression-free-survival-for-treatment-of-platinum-resistant-ovarian-cancer%2F EC145, in combination with pegylated liposomal doxorubicin (Doxil®/Caelyx®) in patients with platinum-resistant ovarian cancer, met its primary endpoint by showing an 85 percent (2.3 month) improvement in median progression-free survival in the intent-to-treat population, and a 260 percent (4.0 month) improvement in a subset of folate receptor positive patients. The final EC145 phase 2 clinical study data were presented [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4902643 Mon, 06 Jun 2011 05:08:29 +0100 4902643 http://www.medworm.com/index.php?rid=4902644&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F04%2F2011-asco-women-with-brca-gene-mutations-can-take-hormone-replacement-therapy-safely-after-ovary-removal%2F Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania Women with the BRCA1 or BRCA2 gene mutations, which are linked [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4902644 Sat, 04 Jun 2011 20:16:50 +0100 4902644 http://www.medworm.com/index.php?rid=4893809&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F03%2F2011-asco-entremed%25e2%2580%2599s-enmd-2076-demonstrates-clinical-activity-in-recurrent-platinum-resistant-ovarian-cancer-patients%2F EntreMed, Inc. announced that ENMD-2076 demonstrated clinical activity — a six-month progression free survival rate of 19% – when administered as a single agent to platinum drug-resistant recurrent ovarian cancer patients. The announcement is based upon interim phase 2 data presented today at the 2011 American Society of Clinical Oncology Annual Meeting.  EntreMed, Inc., a clinical-stage [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4893809 Sat, 04 Jun 2011 05:10:24 +0100 4893809 http://www.medworm.com/index.php?rid=4893810&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F03%2F2011-asco-matching-targeted-therapies-to-specific-tumor-gene-mutations-key-to-personalized-cancer-treatment%2F Customizing targeted therapies to each tumor’s molecular characteristics, instead of a “one-size-fits-all” approach by tumor type, may be more effective for some types of cancer, according to research presented today at the American Society of Clinical Oncology annual meeting by the M.D. Anderson Cancer Center. In patients with end-stage disease, matched patients achieved a 27% [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4893810 Sat, 04 Jun 2011 03:36:14 +0100 4893810 http://www.medworm.com/index.php?rid=4841885&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-genetic-biomarker-predicts-taxane-drug-induced-neuropathy%2F A new study has identified the first genetic biomarkers for taxane-induced peripheral neuropathy, a potentially severe complication of taxane chemotherapy that affects nerves in about one-third of patients with cancer receiving such treatment. ASCO Releases Studies From Upcoming Annual Meeting – Important Advances in Targeted Therapies, Screening, and Personalized Medicine The American Society of Clinical Oncology (ASCO) today highlighted [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841885 Thu, 19 May 2011 23:39:33 +0100 4841885 http://www.medworm.com/index.php?rid=4841886&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-novel-multi-targeted-agent-cabozantinib-xl184-has-significant-effect-on-several-advanced-solid-tumors%2F Cabozantinib (XL184) demonstrated high rates of disease control in patients with prostate, ovarian and liver cancers. The investigators concluded that cabozantinib exhibits clinical activity in ovarian cancer patients with advanced disease, regardless of prior platinum drug status, as reflected by the high rates of response.  ASCO Releases Studies From Upcoming Annual Meeting – Important Advances [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841886 Thu, 19 May 2011 21:53:46 +0100 4841886 http://www.medworm.com/index.php?rid=4841887&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-maintenance-therapy-with-parp-inhibitors-could-play-important-role-in-treatment-of-recurrent-ovarian-cancer%2F A randomized phase II clinical trial showed that the oral PARP inhibitor drug olaparib (AZD2281), given after chemotherapy, improved progression-free survival in women with the most common type of recurrent ovarian cancer. ASCO Releases Studies From Upcoming Annual Meeting – Important Advances in Targeted Therapies, Screening, and Personalized Medicine The American Society of Clinical Oncology (ASCO) today [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841887 Thu, 19 May 2011 18:03:58 +0100 4841887 http://www.medworm.com/index.php?rid=4841888&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2F2011-asco-screening-with-ca-125-transvaginal-ultrasound-does-not-reduce-ovarian-cancer-death-rate-results-in-high-number-of-false-positives%2F Findings from a large, long-term study – the Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial – showed that using a CA-125 blood test and transvaginal ultrasound for early detection of ovarian cancer did not reduce the risk of dying from the disease, and resulted in a large number of false positives and related follow-up [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841888 Thu, 19 May 2011 15:56:18 +0100 4841888 http://www.medworm.com/index.php?rid=4841889&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F18%2F2011-asco-annual-meeting-abstracts-including-ovarian-cancer-made-publicly-available-today%2F More than 30,000 cancer specialists from around the world will gather at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest innovations in research, quality, practice and technology in cancer. More than 30,000 cancer specialists from around the world will gather at the 2011 American Society of Clinical Oncology (ASCO) [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841889 Wed, 18 May 2011 22:43:10 +0100 4841889 http://www.medworm.com/index.php?rid=4658583&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F30%2F2011-aacr-annual-meeting-select-ovarian-cancer-presentations-abstracts-available-online%2F The 102nd American Association For Cancer Research (AACR) Annual Meeting will be held from Saturday, April 2 through Wednesday, April 6, 2011, at the Orange County Convention Center located in Orlando, Florida.  Select ovarian cancer presentations and abstracts are available online. The 102nd American Association For Cancer Research (AACR) Annual Meeting will be held from [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4658583 Wed, 30 Mar 2011 20:23:54 +0100 4658583 http://www.medworm.com/index.php?rid=4592642&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F15%2F2011-nccn-conference-new-treatment-options-lead-to-steady-progress-against-ovarian-cancer%2F Recommendations stemming from recent clinical trials highlight notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Ovarian Cancer at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference. Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4592642 Wed, 16 Mar 2011 01:20:30 +0100 4592642 http://www.medworm.com/index.php?rid=4560519&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F07%2F2011-sgo-annual-meeting-ovarian-cancer-abstracts-selected-for-presentation%2F The March 2011 supplemental issue of Gynecologic Oncology sets forth the ovarian cancer and ovarian cancer-related medical abstracts selected by the Society of Gynecologic Oncologists for presentation at its 42nd Annual Meeting on Women’s Cancer™, which is being held in Orlando, Florida from March 6-9, 2011. The Society of Gynecologic Oncologists (SGO) is hosting its 42nd Annual [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4560519 Tue, 08 Mar 2011 05:39:54 +0100 4560519 http://www.medworm.com/index.php?rid=4179468&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F11%2F17%2Fparp-inhibitor-mk-4827-shows-anti-tumor-activity-in-first-human-clinical-study%2F MK-4827, a new drug that targets proteins responsible for helping cancer cells repair their damaged DNA, has shown promising anti-tumor activity in its first human clinical trial. MK-4827, a new drug that targets proteins responsible for helping cancer cells repair their damaged DNA, has shown promising anti-tumour activity in its first human clinical trial. Some patients with [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4179468 Thu, 18 Nov 2010 06:34:33 +0100 4179468 http://www.medworm.com/index.php?rid=4175920&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F11%2F16%2Fdana-farber-researchers-oncomap-the-way-to-personalized-treatment-for-ovarian-cancer%2F Researchers have shown that point mutations – mis-spellings in a single letter of genetic code – that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalized medicine in which every patient could have their tumor screened, [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4175920 Wed, 17 Nov 2010 07:24:47 +0100 4175920 http://www.medworm.com/index.php?rid=4122024&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F10%2F31%2Fgirls-with-stage-i-ovarian-germ-cell-tumors-can-safely-skip-chemotherapy-until-recurrence%2F Researchers from Dana-Farber/Children’s Hospital Cancer Center found that as many as 50 percent of young girls treated for germ-cell ovarian tumors may be safely spared chemotherapy using a “watch and wait” strategy to determine whether follow-up treatment is needed. Researchers from Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) found that as many as 50 percent of young girls [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4122024 Sun, 31 Oct 2010 22:23:31 +0100 4122024 http://www.medworm.com/index.php?rid=3015439&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F11%2F20%2Fpi3k-pathway-a-potential-ovarian-cancer-therapeutic-target%2F …[T]here are several PI3K signaling pathway targeting drugs in clinical development for use against ovarian cancer and solid tumors, including GDC-0941, BEZ235, SF1126, XL-147, XL-765, BGT226, and PX-866.  The results of two recent medical studies suggest that the use of PI3K-targeted therapies may offer an effective therapeutic approach for patients with advanced-stage and recurrent ovarian [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3015439 Fri, 20 Nov 2009 22:06:25 +0100 3015439 http://www.medworm.com/index.php?rid=2724930&cid=t_121434_111_f&fid=36048&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FdXbPPnOwgFY%2F The health care debate in Washington has really heated up. But one thing I’ve noticed is that people seem to cling to sound bytes to get their news about what’s really going on. Sometimes, the snippets they hear are taken out of context or even completely untrue. To see how much you might now, log on to CNN and take this health care debate quiz. You’ll get an idea of what you know versus what you’ve heard, to see which is the truth. I was surprised at how much I didn’t know. Image: sxc.hu. Post from: Blisstree Health Care Debate Quiz (Source: A Hearty Life) A Hearty Life blogs http://www.medworm.com/rss/comments.php?id=2724930 Fri, 21 Aug 2009 12:36:25 +0100 2724930 http://www.medworm.com/index.php?rid=2688903&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2009%2F08%2F11%2Fdear-acs-journal-editors-please-return-from-vacation-soon%2F The spectacular “NaH catalytic” oxidation recently published in JACS has been thoroughly covered elsewhere. I would like to bring your attention to another jaw-dropping paper that just came out in Org Letters: http://pubs.acs.org/doi/abs/10.1021/ol901250c Acetophenones and 1-aryl-ethanols are oxidized to benzamides by heating the material with 3 – 4 equivs of iodine and ammonia in a pressure vessel. There is only a passing reference and footnote that “nitrogen triodide might form in the mix.” In fact, NI3.NH3 readily precipitates when mixing iodine with aqueous ammonia. (The products vary; a gradual iodine addition to a large excess of ammonia yields ammonium iodide and nitrogen.) Nitrogen triodide is a notoriously super-sensitive primary explosive. I spent fe... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=2688903 Tue, 11 Aug 2009 05:14:37 +0100 2688903 http://www.medworm.com/index.php?rid=2512799&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F06%2F18%2F2009-asco-annual-meeting-highlights-ovarian-cancer-select-general-issues%2F The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009.  We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues. The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2512799 Thu, 18 Jun 2009 22:11:35 +0100 2512799 http://www.medworm.com/index.php?rid=2453074&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F31%2Fearly-treatment-of-recurrent-ovarian-cancer-based-upon-rising-ca-125-levels-does-not-increase-survival%2F “European researchers report [at the 2009 American Society of Clinical Oncology Annual Meeting being held in Orlando, Florida from May 29 through June 2nd] that starting treatment early for an ovarian cancer relapse based on CA125 blood levels alone does not improve overall survival, compared with delaying treatment until symptoms arise.” PLENARY PRESENTATION SUNDAY, MAY 31, 1:45 [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2453074 Sun, 31 May 2009 23:41:47 +0100 2453074 http://www.medworm.com/index.php?rid=2442556&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F21%2Fresearchers-are-on-the-trail-to-killing-cancer-with-genetically-engineered-adult-stem-cells%2F “Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.  The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2442556 Thu, 21 May 2009 20:00:54 +0100 2442556 http://www.medworm.com/index.php?rid=2415713&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F16%2Fginger-quells-cancer-patients-chemotherapy-related-nausea%2F “People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center. …” People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2415713 Sat, 16 May 2009 23:21:44 +0100 2415713 http://www.medworm.com/index.php?rid=2408597&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F14%2F2009-asco-annual-meeting-abstracts-now-available-online%2F The 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held in Orlando, Florida from May 29 through June 2, 2009. The ASCO Annual Meeting will be a forum for cutting-edge scientific and educational developments in oncology with a focus on personalizing cancer care.  The medical abstracts that will be presented [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2408597 Fri, 15 May 2009 01:54:42 +0100 2408597 http://www.medworm.com/index.php?rid=2365437&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2009%2F04%2F22%2Fthe-blockbuster-drugs%2F I would like to direct the readers here to the excellent project-and-career story from Bruce Maryanoff in the most recent J. Med. Chem ASAP. It is very illuminating on how the drug discovery and development works, and it describes in some detail what a bright chemist can hope to achieve in this profession -with the necessary motivation and a decent employer (and tremendous amounts of luck).   It is also an illuminating story on how the process does not work. For example, the currently most popular, target-driven rational-design-based approach can be pretty futile in CNS drug projects . The author also suggests that the management mantra about focusing on the discovery of the next “blockbuster drug” actually bankrupts the industry - financially and scientifically; his drug Topi... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=2365437 Fri, 24 Apr 2009 02:19:47 +0100 2365437 http://www.medworm.com/index.php?rid=2365380&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F23%2Fpreclinical-results-validate-lpathomab-as-a-potential-future-treatment-for-ovarian-cancer%2F “Lpath, Inc. … , the category leader in bioactive-lipid-targeted therapeutics, reported compelling new in vivo and in vitro results relating to its preclinical drug candidate, Lpathomab, in various ovarian cancer studies …” “Lpath Presents Compelling New Preclinical Results of Its Anti-Cancer Drug Candidate, Lpathomab(TM), at the AACR 100th Annual Meeting - New In Vivo and In Vitro [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2365380 Thu, 23 Apr 2009 23:28:32 +0100 2365380 http://www.medworm.com/index.php?rid=2358887&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2009%2F04%2F22%2Fthe-blockbuster-drugs%2F I would like to direct the readers here to the excellent project-and-career story from Bruce Maryanoff in the most recent J. Med. Chem ASAP. It is very illuminating on how the drug discovery and development works, and it describes in some detail what a bright chemist can hope to achieve in this profession -with the necessary motivation and a decent employer (and tremendous amounts of luck).   It is also an illuminating story on how the process does not work. For example, the currently most popular, target-driven rational-design-based approach can be pretty futile in CNS drug projects . The author also not-so-subtly suggests that the management mantra about focusing on the discovery of the next “blockbuster drug” actually bankrupts the industry - financially and scientifically;... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=2358887 Thu, 23 Apr 2009 02:48:00 +0100 2358887 http://www.medworm.com/index.php?rid=2349510&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F20%2Fpersonalized-medicine-helps-breast-colorectal-ovarian-cancer-patients-survive%2F “Cancer patients can survive longer under treatments based on their individual genetic profiles, according to a nationwide study released jointly today by Phoenix-area healthcare organizations. The study shows that molecular profiling of patients can identify specific treatments for individuals, helping keep their cancer in check for significantly longer periods, and in some cases even shrinking [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2349510 Mon, 20 Apr 2009 20:33:00 +0100 2349510 http://www.medworm.com/index.php?rid=2349511&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F20%2Fgenetic-variations-in-mirna-processing-pathway-binding-sites-help-predict-ovarian-cancer-risk%2F “Genetic variations in the micro-RNA (miRNA) processing pathway genes and miRNA binding sites predict a woman’s risk for developing ovarian cancer and her prospects for survival, researchers from The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research. … The unique study was [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2349511 Mon, 20 Apr 2009 18:24:56 +0100 2349511 http://www.medworm.com/index.php?rid=2349513&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F19%2Ftumor-promoting-protein-cox-2-is-the-target-of-first-joint-symposium-between-aacr-asco%2F “An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation’s two premier cancer research organizations.  The presidents of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) organized the session focused on the COX-2 enzyme and cancer treatment Monday [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2349513 Mon, 20 Apr 2009 05:03:52 +0100 2349513 http://www.medworm.com/index.php?rid=2277185&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F16%2Fearly-detection-remains-key-in-updated-national-comprehensive-cancer-network-nccn-guidelines-for-ovarian-cancer%2F New updates to the NCCN Clinical Practice Guidelines in Oncology™ for Ovarian Cancer were presented at the NCCN 14th Annual Conference on March 14. Notable additions to the NCCN Guidelines are a section on managing allergic reactions to chemotherapy agents and new agents for recurrence therapy. Robert J. Morgan Jr., M.D., F.A.C.P. of  the City [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2277185 Mon, 16 Mar 2009 21:23:47 +0100 2277185 http://www.medworm.com/index.php?rid=2205988&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F22%2Flibbys-hopetm-adds-new-cancer-video-archive-courtesy-of-vodpodcom%2F Yesterday, Libby’s H*O*P*E* added a new cancer video archive to the weblog courtesy of Vodpod.com.  Currently, the archive contains approximately 90 videos that address many general cancer and ovarian cancer issues, as well as the personal voices of those affected by cancer. The new video archive is located on the homepage right sidebar.  All you [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2205988 Sun, 22 Feb 2009 17:41:59 +0100 2205988 http://www.medworm.com/index.php?rid=2205989&cid=t_121434_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F21%2F2009-society-of-gynecologic-oncologists-annual-meeting-ovarian-cancer-highlights%2F From February 5th through 8th, 2009, the Society of Gynecologic Oncologists’ (SGO) held its 40th Annual Meeting on Women’s Cancer in San Antonio, Texas. The meeting, viewed as the preeminent scientific and educational conference for women’s cancer care specialists, featured more than 350 scientific oral and poster presentations as well as educational sessions [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2205989 Sun, 22 Feb 2009 01:22:59 +0100 2205989 http://www.medworm.com/index.php?rid=1860079&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F413508790%2F This article was published on Highlight HEALTH. Other Articles You May LikeMore Education Decreases the Risk of Death FDA Attempting to Regulate Dietary SupplementsIncreased Coffee Consumption Associated with Lower Risk of Liver CancerExactly What are Stem Cells?Neurofibromatosis: From Genes to Complications to Treatments (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1860079 Tue, 07 Oct 2008 06:00:21 +0100 1860079 http://www.medworm.com/index.php?rid=1683804&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F356343834%2F This article was published on Highlight HEALTH. Other Articles You May LikeFunding of Childhood Cancer, NF Research in JeopardyCancer PreventionIncreased Coffee Consumption Associated with Lower Risk of Liver CancerExactly What are Stem Cells?The Upside of High Food Prices (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1683804 Wed, 06 Aug 2008 04:25:32 +0100 1683804 http://www.medworm.com/index.php?rid=1677368&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2008%2F08%2F02%2Fa-phosphine-that-will-get-you-fired%2F     Beautiful asymmetric transition metal-catalysed chemistry with phosphine ligands chiral on phosphorus dates back to Knowles and Mislow. But these P-homochiral phosphines are usualy harder to make, so they were eventually supplanted by ligands with chirality on carbon. As a freshman I used to work for a young assistant prof in Prague - and since I was very interested in asymmetric synthesis, he suggested that I could do a thesis work with him on these ligands; We would put some chiral but racemic phosphine building block onto optically active binaphtyl piece derived from BINOL, and we would get BINAP-like ligands with both axial chirality and chirality on phosphorus. We would then try to separate the stereoisomers and see which one worked better in Rh and Ru-cataly... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=1677368 Mon, 04 Aug 2008 06:28:25 +0100 1677368 http://www.medworm.com/index.php?rid=1606789&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F331750090%2F This article was published on Highlight HEALTH. Related articlesHealth Highlights - September 10th, 2007Health Highlights - July 10th, 2007Health Highlights - January 14, 2008Health Highlights - August 9th, 2007Health Highlights - June 16th, 2007 (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1606789 Thu, 10 Jul 2008 13:57:32 +0100 1606789 http://www.medworm.com/index.php?rid=1503033&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F307940708%2F This article was published on Highlight HEALTH. Related articlesHEALTH Highlights - May 6th, 2008Health Highlights - March 3rd, 2008HEALTH Highlights - Monday, December 10thHEALTH Highlights - October 23rd, 2007HEALTH Highlights - August 9th, 2007 (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1503033 Mon, 09 Jun 2008 11:02:05 +0100 1503033 http://www.medworm.com/index.php?rid=1424073&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F284387299%2F This article was published on Highlight HEALTH. Related articlesHEALTH Highlights - September 30th, 2007HEALTH Highlights - August 9th, 2007Health Highlights - March 3rd, 2008Searching for Health Information Online DangerousHEALTH Highlights - January 14, 2008 (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1424073 Tue, 06 May 2008 17:28:47 +0100 1424073 http://www.medworm.com/index.php?rid=1275094&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHEALTH%2F%7E3%2F244951595%2F This article was published on Highlight HEALTH. Related articlesHEALTH Highlights - Monday, December 10thHEALTH Highlights - August 21st, 2007HEALTH Highlights - June 1st, 2007HEALTH Highlights - January 14, 2008The Highlight HEALTH Network (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1275094 Mon, 03 Mar 2008 17:01:43 +0100 1275094 http://www.medworm.com/index.php?rid=1149947&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F216490516%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1149947 Mon, 14 Jan 2008 15:34:25 +0100 1149947 http://www.medworm.com/index.php?rid=1083099&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F197960100%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1083099 Mon, 10 Dec 2007 10:02:35 +0100 1083099 http://www.medworm.com/index.php?rid=971604&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F173822316%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=971604 Tue, 23 Oct 2007 13:45:54 +0100 971604 http://www.medworm.com/index.php?rid=966605&cid=t_121434_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F163563819%2F This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=966605 Mon, 01 Oct 2007 03:49:12 +0100 966605 http://www.medworm.com/index.php?rid=823092&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2007%2F08%2F26%2Fthe-one-phosphine-to-rule-them-all%2F Buchwald et al: Angew Chem Int Ed Eng 45(39) 6523-7 (2006) DOI 10.1002/anie.200601612 Buchwald group developed a number of biphenyl-based phosphine ligands useful for Pd(0)-catalyzed arylations. Descendants from BINAP, these ligands form 1:1 complexes with Pd(0) that are particularly active catalysts, allowing arylations with both poor electrophiles (unactivated aryl chlorides) and lazy nucleophiles (such as heterocycles with very acidic NH). The reason why the bulky monodentate electrone rich 2-biphenyl phosphines are good is that they make Pd(0) more nucleophilic - which helps the Pd insertion into Ar-X - while the bulk promotes the fast migration/dissociation rates in the intermeditate complexes and the formation of PdL2 is supressed. [Even a very sterically hindered PdL complex is c... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=823092 Sun, 26 Aug 2007 20:18:33 +0100 823092 http://www.medworm.com/index.php?rid=728660&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2007%2F06%2F22%2Fdirect-preparation-of-2-aminopyridines-from-n-oxides%2F There is a lovely JOC note from Merck Process group: The N-oxide is transformed to N-tert-butylamino intermediate and then deprotected in situ with TFA in a one-pot operation. The procedure works well with a wide variety of substrates: pyridines, quinolines, isoquinolines. The few examples of unsymmetrically-substituted pyridine-oxides that had both the 2 and 6 positions free provided a mix of the two ortho amino regioisomers. [This is an improved version of the amination procedure with TsCl, NH3 that was useful for 2-aminoquinoline scale-up: Couturier et al, Org Process R & D, 10 (2006), 534-8.] Another related simple procedure for acylamidation of N-oxides from Pfizer process group uses RCONCO that is generated generated in situ from RCONH2 and oxalyl chloride:   This... Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=728660 Fri, 22 Jun 2007 22:54:48 +0100 728660 http://www.medworm.com/index.php?rid=728661&cid=t_121434_149_f&fid=35778&url=http%3A%2F%2Forgprepdaily.wordpress.com%2F2007%2F06%2F17%2Fnew-reactions-from-carreira%2F A fundamentally useful addition reaction that gives good yields with variety of substrates in ethanol at room temperature on a gram scale. Markovnikov product, no stereoselectivity with chiral substrates, no ee’s reported with Jacobsen Co-salene as a catalyst (so probably there aren’t any).  The catalysts are either commercial or 1 step to make. The azides can be transformed to triazoles or amines in situ. Works great with safrole.    (Source: Org Prep Daily) Org Prep Daily blogs http://www.medworm.com/rss/comments.php?id=728661 Sun, 17 Jun 2007 21:52:50 +0100 728661 http://www.medworm.com/index.php?rid=479485&cid=t_121434_107_f&fid=34905&url=http%3A%2F%2Fnatureerratum.typepad.com%2Fnature_erratum%2F2006%2F03%2Fresearch_highli.html Corresponding Author: Fark.com Having cured all genetic diseases, scientists create 50 billion smiley faces using DNA (with pic goodness). Link Smith, LM. Nature 440, 283-284 (2006) Rothemund, PWK. Nature 440, 297–302 (2006) (Source: nature erratum) nature erratum blogs http://www.medworm.com/rss/comments.php?id=479485 Thu, 16 Mar 2006 18:08:24 +0100 479485